Biography:
Dr. Gupta did her BS and MS in India. She then joined Prof. Knud Nierhaus group at Max Planck Institute for Molecular Genetics, Berlin, Germany for her PhD and obtained her degree in the area of ribosome biology and protein translation. After that she worked at Yale University as postdoc where she extensively performed studies to identify new regulator in cancer growth and progression. Many of her studies are published in journals like eLife, PNAS, Cell Reports, Oncogene etc. Currently she is an Assistant Professor in the UAB and Associate scientist at O'Neal Comprehensive Cancer Center at UAB. Her lab Our works on identifying new molecules and pathways and studying their role in tumor initiation and progression. Her long-term goal is to not only identify new molecules and signaling pathways that regulate the disease but also develop more effective and durable cancer therapies.
ATAD2 is a driver and a therapeutic target in ovarian cancer that functions by upregulating CENPE
Co- Targeting of specific epigenetic regulators in combination with CDC7 potently inhibit melanoma growth
DOT1L promotes Ovarian Cancer tumor growth by stimulating pro-tumorigenic metabolic pathways and blocking apoptosis
KLF7 promotes pancreatic cancer growth and metastasis by up - Regulating ISG expression and maintaining Golgi complex integrity